GlassScriptPhysician profile
Mark J Milne
NPI 1538251889
$3,413.38
in general payments reported to CMS, 2019-2025
29 companies · $601 in 2025
The $601 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $196 · 2021: $163 · 2022: $402 · 2023: $664 · 2024: $524 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.23 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $572.90 | 2019-2024 | Myrbetriq, Veozah |
| Teleflex LLC | $416.15 | 2021-2024 | Urolift |
| Myriad Genetic Laboratories, INC. | $328.01 | 2023 | Prolaris |
| Boston Scientific Corporation | $307.89 | 2019-2025 | Advance Xp, Ams 700, Ams 800 Artificial Urinary Sphincter |
| Calyxo, INC. | $222.47 | 2024-2025 | Cvac Aspiration System |
| Urogen Pharma, INC. | $214.03 | 2024-2025 | |
| Janssen Biotech, INC. | $161.02 | 2019-2025 | Erleada, Balversa, Akeega |
| Abbvie INC. | $139.74 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $125.09 | 2025 | Adstiladrin |
| Pfizer INC. | $116.06 | 2019-2025 | |
| Amgen INC. | $97.03 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $84.68 | 2022 | |
| Coloplast Corp | $84.45 | 2020-2025 | Porges Coloplast |
| Neotract INC. | $70.75 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $66.01 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $53.82 | 2023 | |
| Sumitomo Pharma America, INC. | $50.77 | 2023 | Orgovyx |
| Travere Therapeutics, INC. | $39.49 | 2019 | |
| Endo USA, INC. | $38.75 | 2025 | Xiaflex |
| 180 Medical, INC. | $38.69 | 2019-2020 | |
| Tolmar, INC. | $34.06 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $25.74 | 2019 | |
| Allergan, INC. | $23.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.57 | 2024 | |
| Procept Biorobotics Corporation | $23.15 | 2022 | |
| Antares Pharma, INC. | $15.40 | 2025 | Xyosted |
| Caldera Medical, INC | $14.68 | 2023 | Desara |
| Olympus America INC. | $13.61 | 2019 | |
| Urovant Sciences INC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Milne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.